Login
Lost Password?
| Register now!
Register now and gain access to forums and other interactive content geared specifically to medical professionals!
HIV News
-
6/30 - Menopause does not affect response to HIV Tx (aidsmap)
-
6/30 - Adherence to HIV tx in US gay men differs by race and ethnicity (aidsmap)
-
6/30 - Association of HAART w/ increased arterial stiffness in pts with HIV (aidsmap)
-
6/27 - CCR5 Tropism Genotype vs. Trofile (NATAP)
-
6/27 - RAL w/ unboosted ATZ 300mg bid in ARV tx-exp pts (NATAP)
-
6/26 - National HIV/AIDS atlas maps the US epidemic (H&H)
-
6/26 - Newer Anti-HIV Drugs and how to use them: Part 2 (H&H)
-
6/25 - HBV co-infection doesn't affect response to HIV tx (aidsmap)
-
6/23 - Newer Anti-HIV Drugs and How to Use Them: Part I (H&H)
-
6/22 - Good survival for HIV patients diagnosed with non-Hodgkin's lymphoma (aidsmap)
-
6/19 - Simplicaication of HAART to a SRR of EFV/FTC/TDF (H&H)
-
6/17 - Quadrivalent HPV Vaccine May Be Effective in Women 24 to 45 years Old (Medscape)
-
6/17 - Inflammation test can predict heart attacks in people with HIV (aidsmap)
-
6/17 -South Africa: a mixed bag of new HIV figures (aidsmap)
-
6/17 - TB Alliance, Tibotec, form partnership to take forward new drug (aidsmap)
Hepatitis News
- 7/3 - FDA advisory panel urges "Black Box" warning - and potential ban - on prescription acetaminophen combos due to liver toxicity (H&H)
- 7/1 - Liver CA rates triple: HCC Incidence, Mortality and Survival trends in the US from 1975 to 2005 (NATAP)
- 6/30 - FDA Loosens Up HCV Drug Development - HCV Boston Meeting June 27, 2009 (NATAP)
- 6/29 - Randomized Trial Comparing Systemic and Local Reactions to Controlled-release IFN-alpha2b and PegIFN alpha2b in HCV Pts Who Failed Prior Treatment (NATAP)
- 6/25 - Hepatitis B co-infection doesn't affect response to HIV treatment (aidsmap)
- 6/23 - HAART may reduce liver inflammation in HIV/HCV coinfected pts with high CD4 (H&H)
- 6/23 - Detectable HCV RNA at week 8 is best predictor of relapse in genotype 1 HCV Pts treated with pegIFN/RBV (H&H)
- 6/23 - CDC researchers release latest Hep A, B, and C Stats (H&H)
- 6/21 - Early serum HBsAg drop: A strong predictor fo SVR to pegIFN alfa-2a in HBeAg-neg pts (NATAP)
- 6/21 - HBsAg decline appears to predict clearance - Increasing rates of HBsAg clearance and seroconversion in pts with HBeAg-neg disease treated with PegIFN alfa-2a +/- LAM: Results of 5-yr post-tx f/u (NATAP)
- 6/21 - Baseline HBsAg Level Predict HBsAg Loss in CHB Pts Treated with a Combo of PegIFN Alfa-2A and ADF: An Interim Analysis (NATAP)
- 6/21 - Benefits and risks of IFN therapy for HBV Meeting Report Review Robert Perillo (NATAP)
- 6/20 - Retreating CHC w/ daily IFN alfacon-1/RBV after nonresonse to PegIFN/RBV: DIRECT results (NATAP)
- 6/20 - Incidence Rates and Risk Factors: Associated with HCC in Patients with Advanced Liver Disease Due to HCV: Results of HALTC Trial; Is the Study Design Flawed? (NATAP)
- 6/20 - Telaprevir in HCV Genotype-1 Infected Pts with Prior Non-response, Viral Breakthrough or Relapse to PegIFN-alfa-2A/B and RBV Therapy: SVR Results of the PROVE3 Study (NATAP)
- 6/20 - Telaprevir with PegIFN and RBV for CHC Genotype 1 Infection - PROVE1 in NEJM 4/2009 (NATAP)
- 6/19 - Effectiveness of peg-IFN plus RBV for CHC with HCV genotypes 5 or 6 (H&H)
- 6/19 - Blood pressure drug Losartan associated with liver fibrosis regression in small study (H&H)
- 6/19 - HAART may reduce liver inflammation in HIV/HCV coinfected patients with high CD4 cell counts (H&H)
- 6/17 - Risk and Predictors of HCC in People Less than 40 yo: Update from the REVEAL-HBV Study (NATAP)
- 6/17 - Association between HBV Replication and Serum ALT Changes is not Dependent on HBV Genotype and Mutants (NATAP)
-
[2009/5/1]
44th EASL 2009
The 44th EASL conference is now over and new information will be available soon. Watch for the upcoming newsletter and... -
[2009/3/25]
HBV Debate 2009
HBV Treatment Controversies in 2009: A Debate registration is now opened for LIVE lecture dinner programs. Please go to ... -
[2009/3/16]
HBV Treatment Debate
Preparing for the launch of the lecture series and on-line CME program entitled HBV Treatment Controversies in 2009: A D... -
[2009/3/16]
CV Health in HIV
Maintaining Cardiovascular Health in HIV-positive Patients: An interactive meeting to discuss assessment and management ...
Featured Programs
HBV Treatment Controversies in 2009:
A Debate
Chronic hepatitis B (CHB) afflicts 350 million persons worldwide and an estimated 1.25 million individuals in the US. The health and well-being of these patients depends upon their clinician being knowledgeable regarding the significant advances in the diagnosis and treatment of CHB that have occurred in the past five years.
This program is designed to provide clinically-relevant education on these and other CHB-related topics in a novel and effective presidential-debate style format which will feature two nationally known and recognized CHB experts.
Sponsored For CME Credit By:
Supported by an Unrestricted Educational Grant From Gilead Sciences
These programs review studies on ARV therapies and therapeutic strategies presented at the 16th Conference on Retroviruses and Opportunistic Infection. These programs feature a distinguished faculty, including John Bartlett MD, David Cooper MD, Jurgen Rockstroh MD, Joseph Eron MD, Calvin Cohen MD, Paul Sax MD, Richard Elion MD, Edwin DeJesus MD, Graeme Moyle MD and Ian Frank MD. They are all sponsored for CME credit for US physicians by The Johns Hopkins University School of Medicine. The information in this educational activity was planned and produced in accordance with ACCME Essentials.
Sponsored For CME Credit By:
Supported by an educational grant from Merck & Co.
Maintaining Cardiovascular Health In HIV-Postive Patients
As HIV-positive individuals live longer due to the use of highly active antiretroviral therapy (HAART), coronary heart disease (CHD) has become an increasingly important and pressing concern. This program will review and explain risk assessment, management and potential avoidance of CHD in HIV-positive patients. A cardiologist and an HIV expert will discuss and explore the risks associated with CHD in these patients and effective strategies and treatments for reducing or avoiding those risks. The most recent data regarding CHD in HIV-positive patients will be presented, including those presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), along with highly interactive case studies.
Sponsored For CME Credit By:
Supported by an Unrestricted Educational Grant From Gilead Sciences
Maximizing Success
While Preserving Future Options:
Debating Antiretroviral Treatment Options
This online CME program, sponsored for CME credit by Johns Hopkins University School of Medicine, will explore important issues surrounding ARV choices and resistance. Included in the program will be a debate and discussion of recently presented data which will challenge participants to re-examine their beliefs and theories on viral efficacy and the contribution of various factors to long-term virologic control and preservation of future treatment options.
Sponsored For CME Credit By:
Supported by an educational grant from Tibotec
Expert Summaries of the
48th ICAAC / 46th IDSA and HIV-9
The 48th ICAAC and HIV-9 provide new research and therapeutic developments in HIV and an opportunity for those involved in the evaluation and treatment of HIV-infected patients to learn of the most recent advances in HIV research and treatment. This program provides expert commentary and insight regarding the data presented at these conferences through newsletters and a downloadable podcast and slide deck summarizing some of the key studies regarding the treatment of ARV-naïve and –experienced patients. The learning objectives of the programs are:
- To be able to understand, describe and explain the key new studies presented at the 48th ICAAC/46th IDSA and/or HIV-9 on the treatment of HIV
- To be able to use the advances in clinical management of HIV-positive patients presented and discussed at the 48th ICAAC/46th IDSA and/or HIV-9 to improve patient care
- To be able to analyze and apply data presented and discussed at the 48th ICAAC/46th IDSA and/or HIV-9 regarding the treatment of ARV-experienced patients to analyze treatment options and construct appropriate ARV
Sponsored For CME Credit By:
Supported by an educational grant from Merck & Co.
Therapeutic Strategies for Antiretroviral Treatment Experienced Patients: A Case Based Approach
This program, sponsored for CME credit by Rush University Medical Center entitled: "Therapeutic Strategies for Antiretroviral Treatment Experienced Patients" is available for clinicians interested in the clinical management of antiretroviral-experienced HIV patients. The information in this educational activity was planned and produced in accordance with ACCME Essentials. Issues surrounding the care of ARV treatment experienced patients will be presented in lecture, case-based presentation and group discussion formats by a distinguished faculty.
Sponsored For CME Credit By:
Supported by an Unrestricted Educational Grant From:
Changing ARV Therapy in Patients with an Undetectable Viral Load: A Debate
This presidential-style debate, featuring 2 nationally known speakers and a local moderator, will explore whether to change or stay the course with ARV therapy in a patient with an HIV RNA <50 c/mL.
Debate includes a discussion of recent data, including those from the 15th CROI, which indicate the potential positive and negative effects of changing ARV therapy in a fully suppressed patient.
Sponsored For CME Credit By:
Supported by an Unrestricted Educational Grant From Gilead Sciences
- Individualizing Care in HIV: A Critical Review of Treatment Options
June 10-July 15, 2009 Lecture Series USA - Register Now - EASL 44th Annual Meeting
April 22-26, 2009 - Newsletter and Webcast
Copenhagen, Denmark - HBV Treatment Controversies in 2009: A Debate
April 14 - August 4, 2009 Lecture Series USA - Register Now - Maintaining CV Health in HIV+ Patients
On-Line CME Available Now
March 18-May 6, 2009 Lecture Series, USA - Now Completed - 16th Conference on Retroviruses and Opportunistic Infections
February 8-11, 2009, Montreal, Canada
On-Line newsletter and Webcast symposium available now - Maximizing Success While Preserving Future Options
A ViralEd CME Program available now - HIV 9th International Congress on Drug Therapy in HIV Infection
November 9-13, 2008, Glasgo, UK
CME On-Line Available Now - 48th Annual ICAAC /IDSA 46th Annual Meeting
October 25-28, 2008, Washington, DC, USA
On-Line CME available now - Therapeutic Strategies for Antiretroviral Treatment Experienced Patients: A Case Based Approach
- XVII International AIDS Conference
August 3-8, 2008, Mexico City, Mexico
On-Line CME available now - Changing ARV Therapy in Patients with an Undetectable Viral Load: A Debate
July 15, 2008 - July 15, 2009
On-Line CME available now
- IAS 5th Conference on HIV Pathogenesis, Treatment and Prevention
July 19-22, 2009
Cape Town, South Africa - ICAAC 49th Annual Meeting
September 12-15, 2009
San Francisco, CA USA - IDSA 47th Annual Meeting
October 29 - November 1, 2009
Philadelphia, PA USA